Review of Pemphigus Vulgaris Management
DOI:
https://doi.org/10.58931/cdt.2025.61133Abstract
Pemphigus Vulgaris (PV) is an autoimmune blistering disease that is characterized by painful erosions and flaccid blisters involving the mucous membranes and skin (Figure 1). The production of pathogenic immunoglobulin autoantibodies, mainly IgG4, against the desmosomal cadherins desmoglein 1 (Dsg-1) and desmoglein 3 (Dsg‑3), lead to the loss of epidermal keratinocyte adhesion. In the mucosal dominant type, Dsg-3 antibodies are present, while in the mucocutaneous type, antibodies against both desmoglein 1 and 3 are found. Diagnosing PV requires compatible clinical features, histopathological examination of the involved skin, and the detection of autoantibodies by indirect immunofluorescence of non-affected peri-lesional skin. The pemphigus disease area index (PDAI) and the autoimmune bullous skin disorder intensity score (ABSIS) provide a standardized assessment of disease extent and response to treatment. A treatment algorithm has been proposed for PV (Figure 2 and Figure 3). In addition, supportive management is also important (Table 1).
References
Murrell DF, Peña S, Joly P, Marinovic B, Hashimoto T, Diaz LA, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020;82(3):575-585.e1. doi:10.1016/j.jaad.2018.02.021.
Harman KE, Albert S, Black MM; British Association of Dermatologists. Guidelines for the management of pemphigus vulgaris. Br J Dermatol. 2003;149(5):926-937. doi:10.1111/j.1365-2133.2003.05665.x.
Joly P, Horvath B, Patsatsi Α, Uzun S, Bech R, Beissert S, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900-1913. doi:10.1111/jdv.16752.
Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori Let al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol. 2008;58(6):1043-1046. doi:10.1016/j.jaad.2008.01.012.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031-2040. doi:10.1016/S0140-6736(17)30070-3.
Werth VP, Joly P, Mimouni D, Maverakis E, Caux F, Lehane P, et al. Rituximab versus mycophenolate mofetil in patients with pemphigus vulgaris. N Engl J Med. 2021;384(24):2295-2305. doi:10.1056/NEJMoa2028564.
Lee MS, Yeh YC, Tu YK, Chan TC. Network meta-analysis-based comparison of first-line steroid-sparing adjuvants in the treatment of pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2021;85(1):176-186. doi:10.1016/j.jaad.2020.08.028.
Chams-Davatchi C, Esmaili N, Daneshpazhooh M, Valikhani M, Balighi K, Hallaji Z, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol. 2007;57(4):622-628. doi: 10.1016/j.jaad.2007.05.024.
Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M, Davatchi F, Balighi K, Esmaili N, et al. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol. 2013;27(10):1285-1292. doi:10.1111/j.1468-3083.2012.04717.x.
Martin LK, Werth VP, Villaneuva EV, Murrell DF. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol. 2011;64(5):903-908. doi:10.1016/j.jaad.2010.04.039.
Ioannides D, Apalla Z, Lazaridou E, Rigopoulos D. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study. J Eur Acad Dermatol Venereol. 2012;26(7):855-860. doi:10.1111/j.1468-3083.2011.04170.x.
Yuan H, Pan M, Chen H, Mao X. Immunotherapy for pemphigus: present and future. Front Med (Lausanne). 2022;9:901239. doi:10.3389/fmed.2022.901239.
Amagai M, Ikeda S, Shimizu H, Iizuka H, Hanada K, Aiba S, et al. A randomized double- blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol. 2009;60(4):595-603. doi:10.1016/j.jaad.2008.09.052.
Chams-Davatchi C, Valikhani M, Daneshpazhooh M, Esmaili N, Balighi K, Hallaji Z, et al. Pemphigus: analysis of 1209 cases. Int J Dermatol. 2005;44(6):470-476. doi:10.1111/j.1365-4632.2004.02501.x.
Didona D, Maglie R, Eming R, Hertl M. Pemphigus: current and future therapeutic strategies. Front Immunol. 2019;10:1418. doi:10.3389/fimmu.2019.01418.
Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353(6295):179-184. doi:10.1126/science.aaf6756 .
Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE, et al. 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–1537. doi:10.1002/art.40137.
Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515-1526. doi:10.1002/acr.20295
Lehman JS, Kalaaji AN. Role of primary prophylaxis for pneumocystis pneumonia in patients treated with systemic corticosteroids or other immunosuppressive agents for immune-mediated dermatologic conditions. J. Am. Acad. Dermatol. 2010;63(5):815-823. doi:10.1016/j.jaad.2009.11.588.
National Center for Immunization and Respiratory Diseases. General recommendations on immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2011;60(2):1–64
Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66(7):1016–1026. doi:10.1002/acr.22246.
